Design and Antimalarial Evaluation of Polydopamine-Modified Methyl Artelinate Nanoparticles DOI

Q. Y. Li,

Rongrong Wang,

Shuqi Han

et al.

Molecular Pharmaceutics, Journal Year: 2024, Volume and Issue: 21(11), P. 5551 - 5564

Published: Oct. 8, 2024

Targeted nanodrug delivery systems are highly anticipated for the treatment of malaria. It is known that Plasmodium can induce new permeability pathways (NPPs) on membrane infected red blood cells (iRBCs) their nutrient uptake. The NPPs also enable uptake nanoparticles (NPs) smaller than 80 nm. Additionally, maintains a stable, slightly acidic, and reductive internal environment with higher glutathione (GSH) levels. Based this knowledge, methyl artelinate (MA, prodrug-like derivative dihydroartemisinin) (MA-PCL-NPs) were developed using poly(ethylene glycol)-b-poly(ε-caprolactone) (mPEG-PCL) by thin-film dispersion method further coated polydopamine (PDA) to obtain MA-PCL@PDA-NPs particle size ∼30 biomaterial PDA be degraded in acidic environments, thereby serving as triggers drug release. MA could generate reactive oxygen species decrease GSH levels, consequently causing parasite damage. vitro release experiment results indicated cumulative percentage from was considerably phosphate buffer 10 mM at pH 5.5 (88.10%) without 7.4 (16.98%). green fluorescence within iRBCs coumarin 6, probe NPs (C6-PCL@PDA-NPs), reduced significantly after adding NPP inhibitor furosemide (p < 0.001), which demonstrated ingested into through NPPs. In vivo antimalarial pharmacodynamics berghei K173-bearing mice showed inhibition ratio (93.96%) commercial artesunate injection (AS-Inj, 63.33%). above possessed pH-GSH dual-responsive characteristics targeting efficacy iRBCs, leading against Plasmodium.

Language: Английский

A novel silkworm excrement-derived nanomedicine integrating ferroptosis and photodynamic therapy, well-suitable for PD-L1-mediated immune checkpoint blockade DOI
Yujun Bao, Guanghao Li, Mingyang Liu

et al.

Chemical Engineering Journal, Journal Year: 2025, Volume and Issue: 505, P. 159676 - 159676

Published: Jan. 17, 2025

Language: Английский

Citations

2
Chitosan and hyaluronic acid in breast cancer treatment: Anticancer efficacy and nanoparticle and hydrogel development DOI
Yanlin Jiang, Yu Cao, Yiqun Yao

et al.

International Journal of Biological Macromolecules, Journal Year: 2025, Volume and Issue: 301, P. 140144 - 140144

Published: Jan. 21, 2025

Language: Английский

Citations

1
Highly efficient tumor oxygen supplementation MnO2 nano-MOF encapsulated Sorafenib for multiple synergistic CDT/PDT/RT DOI

Shuangshuang Guo,

Miaomiao Chen, Yuhao Yang

et al.

International Journal of Pharmaceutics, Journal Year: 2025, Volume and Issue: unknown, P. 125328 - 125328

Published: Feb. 1, 2025

Language: Английский

Citations

0
Engineered Photoactivatable Nanomicelles for Ferroptosis-like Combinational Tumor Therapy In Vitro and In Vivo DOI
Yandai Lin, Xinru Kong, Zhe Liu

et al.

ACS Applied Materials & Interfaces, Journal Year: 2025, Volume and Issue: unknown

Published: March 20, 2025

Nitric oxide (NO)-based gas therapy has attracted increasing attention as a promising approach for tumor treatment, but elevated levels of glutathione (GSH) in the microenvironment significantly limit their therapeutic effectiveness. In this study, type engineered photoactivatable nanomicelles Ce6/NI@PEP@HA (CNPH) were developed combinational photodynamic and NO therapy. CNPH was capable targeted accumulation to tumors, where it depleted GSH released effectively produce reactive oxygen species (ROS) with oxidative damage under laser irradiation at 660 nm. The consumption induced deactivation peroxidase activity, leading enhanced toxic lipid peroxide enabled ferroptosis-like outcome. Additionally, effective production ROS resulted mitochondrial dysfunction, characterized by disruption membrane potential decreased adenosine triphosphate concentration. vivo animal experiments indicated that achieved inhibition 89.1%, proven be more strategy contrast any single modality. consequence, opened up new horizon cutting-edge noninvasive paradigm advanced treatments.

Language: Английский

Citations

0
Dual-drug loaded hyaluronic acid conjugates coated polydopamine nanodrugs for synergistic chemo-photothermal therapy in triple negative breast cancer DOI
Min Li, Khoi Chu, Qin Zhou

et al.

International Journal of Biological Macromolecules, Journal Year: 2025, Volume and Issue: 308, P. 142559 - 142559

Published: March 28, 2025

Language: Английский

Citations

0
pH- and redox-sensitive selenium-incorporated mesoporous silica nanoparticles for osteosarcoma-targeted treatment DOI Creative Commons
Le He,

Zahra Javid Anbardan,

Pamela Habibović

et al.

Materials & Design, Journal Year: 2025, Volume and Issue: unknown, P. 113883 - 113883

Published: March 1, 2025

Language: Английский

Citations

0
Self-assembled nanoplatform-mediated co-delivery of brusatol to sensitize sorafenib for hepatocellular carcinoma treatment DOI Creative Commons
Fengrui Liu, Senlin Li,

Chengcheng Huang

et al.

RSC Advances, Journal Year: 2025, Volume and Issue: 15(15), P. 11675 - 11687

Published: Jan. 1, 2025

We developed a glutathione (GSH) responsive nanoplatform for the co-delivery of sorafenib (Sor) and brusatol (Bru). This enhanced Bru’s efficacy increased Sor’s sensitivity. innovative approach effectiveness in hepatocellular carcinoma (HCC) treatment.

Language: Английский

Citations

0
Design and Antimalarial Evaluation of Polydopamine-Modified Methyl Artelinate Nanoparticles DOI

Q. Y. Li,

Rongrong Wang,

Shuqi Han

et al.

Molecular Pharmaceutics, Journal Year: 2024, Volume and Issue: 21(11), P. 5551 - 5564

Published: Oct. 8, 2024

Targeted nanodrug delivery systems are highly anticipated for the treatment of malaria. It is known that Plasmodium can induce new permeability pathways (NPPs) on membrane infected red blood cells (iRBCs) their nutrient uptake. The NPPs also enable uptake nanoparticles (NPs) smaller than 80 nm. Additionally, maintains a stable, slightly acidic, and reductive internal environment with higher glutathione (GSH) levels. Based this knowledge, methyl artelinate (MA, prodrug-like derivative dihydroartemisinin) (MA-PCL-NPs) were developed using poly(ethylene glycol)-b-poly(ε-caprolactone) (mPEG-PCL) by thin-film dispersion method further coated polydopamine (PDA) to obtain MA-PCL@PDA-NPs particle size ∼30 biomaterial PDA be degraded in acidic environments, thereby serving as triggers drug release. MA could generate reactive oxygen species decrease GSH levels, consequently causing parasite damage. vitro release experiment results indicated cumulative percentage from was considerably phosphate buffer 10 mM at pH 5.5 (88.10%) without 7.4 (16.98%). green fluorescence within iRBCs coumarin 6, probe NPs (C6-PCL@PDA-NPs), reduced significantly after adding NPP inhibitor furosemide (p < 0.001), which demonstrated ingested into through NPPs. In vivo antimalarial pharmacodynamics berghei K173-bearing mice showed inhibition ratio (93.96%) commercial artesunate injection (AS-Inj, 63.33%). above possessed pH-GSH dual-responsive characteristics targeting efficacy iRBCs, leading against Plasmodium.

Language: Английский

Citations

1